You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Interferon-beta

Showing 1 - 25 of 4,937
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Sclerosis Trial in Cairo (Blood sample collection)

Recruiting
  • Multiple Sclerosis
  • Blood sample collection
  • Cairo, Egypt
    Nasser Institute for Research and Treatment
Feb 21, 2023

Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia Trial

Not yet recruiting
  • Recurrent B Acute Lymphoblastic Leukemia
  • +5 more
  • Interferon Beta-1A
  • +10 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 6, 2023

Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma AJCC v7 Trial in Seattle (drug, other, biological, radiation)

Terminated
Has Results
  • Merkel Cell Polyomavirus Infection
  • Stage IV Merkel Cell Carcinoma AJCC v7
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Feb 25, 2022

Covid19 Trial in United States (IFN beta-1a, Dexamethasone)

Terminated
Has Results
  • Covid19
  • Aurora, Colorado
  • +3 more
Oct 13, 2022

Learn About Interferon-beta Exposure of Pregnant Women During

Not yet recruiting
  • Multiple Sclerosis (MS)
  • Avonex (IFNβ-1-a, Biogen Netherlands B.V)
  • +5 more
  • Multiple Locations, Finland
  • +1 more
Sep 19, 2023

Multiple Sclerosis Trial in Shreveport (Interferon beta 1a, oral doxycycline)

Completed
Has Results
  • Multiple Sclerosis
  • Interferon beta 1a, oral doxycycline
  • Shreveport, Louisiana
    LSU Health Sciences Center Shreveport
Oct 11, 2022

Healthy Subjects, Pharmacokinetics, Pharmacodynamics Trial in West Bend (Interferon beta-1a, Peginterferon beta-1a, Placebo)

Completed
  • Healthy Subjects
  • +2 more
  • Interferon beta-1a
  • +2 more
  • West Bend, Wisconsin
    Spaulding Clinical Research
Aug 16, 2021

Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Recruiting
  • Multiple Sclerosis
  • Diroximel Fumarate
  • +8 more
  • Eden Prairie, Minnesota
    OptumInsight
Jan 9, 2023

Relapsing Remitting Multiple Sclerosis (RRMS) Trial in Tehran (Pegylated interferon beta-1a, Interferon Beta-1A Prefilled

Active, not recruiting
  • Relapsing Remitting Multiple Sclerosis (RRMS)
  • Pegylated interferon beta-1a
  • Interferon Beta-1A Prefilled Syringe
  • Tehran, Iran, Islamic Republic of
    Sina Hospital
Feb 5, 2022

Female Participants Exposed to Subcutaneous Peginterferon

Completed
  • Multiple Sclerosis
  • Multiple Sclerosis, Relapsing-Remitting
  • Interferon Beta Therapy
  • Göttingen, Germany
    Research Site
Nov 1, 2021

Multiple Sclerosis Trial (Diroximel Fumarate, Avonex, Tysabri)

Not yet recruiting
  • Multiple Sclerosis
  • Diroximel Fumarate
  • +3 more
  • (no location specified)
Dec 12, 2022

Sarcoma, Kaposi, HIV Trial in Los Angeles, Chicago (Interferon beta-1b, Zidovudine)

Completed
  • Sarcoma, Kaposi
  • HIV Infections
  • Los Angeles, California
  • +3 more
Oct 26, 2021

Advanced Malignant Solid Tumor, Hepatocellular Carcinoma Trial in Scottsdale (Laboratory Biomarker Analysis, Pharmacological

Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • Hepatocellular Carcinoma
  • Laboratory Biomarker Analysis
  • +2 more
  • Scottsdale, Arizona
    Mayo Clinic in Arizona
Oct 6, 2021

Multiple Sclerosis, Relapsing-Remitting Trial in Nizhny Novgorod (BCD-054 180 mcg, Avonex®, BCD-054 240 mcg)

Completed
  • Multiple Sclerosis, Relapsing-Remitting
  • BCD-054 180 mcg
  • +3 more
  • Nizhny Novgorod, Russian Federation
    State Budgetary Healthcare Institution of Nizhny Novgorod region
Sep 6, 2021

Relapsing-remitting Multiple Sclerosis Trial in Stockholm (Rituximab)

Active, not recruiting
  • Relapsing-remitting Multiple Sclerosis
  • Stockholm, Sweden
    Fredrik Piehl
Apr 8, 2022

Relapsing Multiple Sclerosis Trial (Placebo, BIIB061, Interferon-beta1)

Not yet recruiting
  • Relapsing Multiple Sclerosis
  • Placebo
  • +3 more
  • (no location specified)
Mar 22, 2021

US PROmyBETAapp2.0: A Study to Learn More About Medication Usage

Completed
  • Multiple Sclerosis
  • Interferon-beta-1b (BETASERON, BAY 86-5046)
  • Whippany, New Jersey
    myBETAapp
Mar 2, 2022

Multiple Sclerosis Trial in Berlin, Potsdam (Verum arm receiving Gilenya®, Active Comparator receiving Extavia®)

Terminated
  • Multiple Sclerosis
  • Verum arm receiving Gilenya®
  • Active Comparator receiving Extavia®
  • Berlin, Germany
  • +1 more
Jul 28, 2021

COVID-19, INTERFERON, NEBULIZATION Trial in France (inhaled type I interferon, WFI water nebulization)

Recruiting
  • COVID-19
  • +2 more
  • inhaled type I interferon
  • WFI water nebulization
  • Abbeville, France
  • +6 more
Jan 3, 2022

Relapsing-remitting Multiple Sclerosis Trial in Rockland, Darmstadt (Evobrutinib, Avonex®, Avonex® matched Placebo)

Terminated
Has Results
  • Relapsing-remitting Multiple Sclerosis
  • Rockland, Massachusetts
  • +1 more
Jul 13, 2021

Relapsing-remitting Multiple Sclerosis Trial in Rockland, Darmstadt (Evobrutinib, Avonex®, Avonex® matched Placebo)

Terminated
Has Results
  • Relapsing-remitting Multiple Sclerosis
  • Rockland, Massachusetts
  • +1 more
Jul 13, 2021

Covid19 Trial in Kingston (Remdesivir, Acalabrutinib, Interferon beta-1a)

Not yet recruiting
  • Covid19
  • Kingston, Jamaica
    Univeristy of the West Indies
May 10, 2021

Preventive Medicine, Multi Organ Failure Trial in Estonia, Finland, Lithuania (Interferon Beta-1A, Placebo)

Terminated
Has Results
  • Preventive Medicine
  • Multi Organ Failure
  • Interferon Beta-1A
  • Placebo
  • Tartu, Estonia
  • +8 more
Dec 22, 2020

Interferon Beta-1a on Changes of Non-conventional MRI Measures

Completed
  • Multiple Sclerosis
  • Avonex® monotherapy (6.0 MIU administered i.m. each week)
  • Buffalo, New York
    The Jacobs Neurological Institute
Dec 23, 2020

Multiple Sclerosis, Relapsing-Remitting Trial in Kocaeli (EK-12, INF beta-1a)

Recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • Kocaeli, Turkey
    Kocaeli University, Faculty of Medicine, Department of Neurology
Jul 23, 2021